Wall St futures flat amid US-China trade jitters; bank earnings in focus
Director Ann D. Rhoads of Globus Medical Inc (NASDAQ:GMED) sold 10,000 shares of Class A Common Stock on September 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $58.46, resulting in a total transaction value of $584,600. The transaction comes as the stock trades near $57.84, down approximately 30% year-to-date, though InvestingPro analysis suggests the stock is currently undervalued.
The prices for the transactions ranged from $58.22 to $58.81. Following the sale, Rhoads directly owns 25,384 shares of Globus Medical . While this insider sale may raise questions, InvestingPro data shows the company maintains strong fundamentals with a 67% gross profit margin and excellent financial health scores. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report.
The sale was executed under a Rule 10b5-1 trading plan established on November 8, 2024. The company, with a market capitalization of $7.8 billion, operates with minimal debt and maintains strong liquidity, as evidenced by its current ratio of 4.07.
In other recent news, Globus Medical reported its second-quarter 2025 financial results, which exceeded analysts’ expectations. The company announced an adjusted earnings per share of $0.86, surpassing the consensus estimate of $0.75 by approximately 15%. Revenue for the quarter reached $745.3 million, slightly above the anticipated $739.16 million. This performance reflects a total sales growth of 3% year-over-year, or 5% when adjusted for the number of business days. Meanwhile, Citizens JMP has reiterated its Market Perform rating for Globus Medical following these results. The firm’s analysis indicates confidence in the company’s current market position. These developments highlight recent positive trends for Globus Medical, capturing attention in the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.